Get started

Johnsonandjohnson

Johnson & Johnson | JNJ | Long at $146.00Johnson & Johnson NYSE:JNJ is strong (but highly controversial) company with anticipated earnings growth on the horizon. With a P/E of 23x, steady dividend growth record, low debt, and expected increased cashflow, the future is optimistic for NYSE:JNJ if they can stay out of the shady spotlight... While the historical simple moving average I've selected suggests the stock is entering a downtrend on the daily chart, I'm going to go against this given the current price/position it is in. If the price can hold in $140's and then move up, there could be an early cup formation here. However, if the price drops below $140, that idea is out, and the near-term downtrend may be on. But the company, overall, is a personal buy-and-hold for the long-term ups and downs (unless new news points the company in a different direction). Thus, at $146.00, NYSE:JNJ is in a personal buy-zone. Target #1 = $157.00 Target #2 = $165.00 Target #3 = $170.00+
NYSE:JNJLong
by WorthlessViews
JOHNSON & JOHNSON Excellent confirmed sell signalJohnson & Johnson (JNJ) gave us the most optimal buy entry on our last call (April 17, see chart below) and easily hit our 157.50 Target: Having been rejected early in September exactly at the top (Lower Highs trend-line) of the 2-year Channel Down and now establishing price action below its 1D MA50 (blue trend-line), this is a confirmed sell signal and the start of the Channel's 5th Bearish Leg. The RSI Lower Highs are common on all previous Channel tops. Our Target is 141.00, which is on the Internal Lower Lows trend-line (formed by the last 2 Lower Lows) and still above the 1.236 Fibonacci extension. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:JNJShort
by TradingShot
Johnson & Johnson (JNJ) - Approaching the Reversal ZoneIn April, we anticipated a pullback for JNJ, and since then, the stock has dropped approximately 7%, aligning with our expectations. The current trend suggests further downward movement, reinforcing our previous analysis. We are focusing on the support zone ranging from $134 to $116, with a potential lower bound at $109, the Corona-Low. The ongoing pullback could represent the completion of Wave (4) within this target zone, aligning with multiple levels. We are going to be monitoring this for signs of a reversal within this zone. This zone will be crucial to confirm the next possible upward movement.
NYSE:JNJLong
by freeguy_by_wmc
1
JOHNSON & JOHNSON Time to start buying.Johnson & Johnson (JNJ) quickly hit the $147.00 Target that we set on our very recent sell call (April 03, see chart below) and is now approaching the bottom of the massive 2-year Channel Down: Even though based on the very reliable and consistent Sine Waves, the bottom might be a process that can take up to 2-months, the stock is low enough for medium-term investors to start considering adding buys. On top of that, the 1D RSI is highly oversold below 20.00, the lowest it has been in more than 4 years (since February 28 2020)! As a result and since the Bearish Legs of this Channel Down have ranged within -14.78% and -17.58%, we are turning bullish on this stock, targeting $157.50 (minimum +13.00% rise as with January 22 2024 High). ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:JNJLong
by TradingShot
Rallybio's Breakthrough Collaboration Drives $RLYB Stock SurgeRallybio Corporation (Nasdaq: NASDAQ:RLYB ) is hitting the accelerator pedal after announcing a groundbreaking collaboration with Johnson & Johnson to combat fetal and neonatal alloimmune thrombocytopenia (FNAIT). In a strategic move aimed at advancing therapeutic solutions for pregnant individuals at risk of FNAIT, Rallybio revealed plans for RLYB212, a revolutionary human monoclonal antibody designed to prevent alloimmunization and eliminate the risk of FNAIT in fetuses and newborns. The partnership with Johnson & Johnson not only includes a significant equity investment but also underscores a joint commitment to tackle this severe and rare disease. Rallybio's CEO, Stephen Uden, expressed enthusiasm about the collaboration, emphasizing its potential to drive awareness, accelerate research, and ultimately, eradicate FNAIT. RLYB212 stands out as the only investigational therapy targeting pregnant individuals at risk of FNAIT who have not yet alloimmunized. This innovative approach complements Johnson & Johnson's ongoing Phase 3 study of nipocalimab, targeting FcRn, in pregnant individuals already alloimmunized. Rallybio's natural history study is a crucial step in gathering data to support future registration of RLYB212. The study's focus on a diverse population underscores the company's commitment to inclusivity and comprehensive research. The collaboration between Rallybio and Johnson & Johnson represents a significant leap forward in addressing FNAIT, offering hope to pregnant individuals and their newborns. As Rallybio continues to drive innovation in therapeutic solutions, investors are optimistic about the company's potential to transform the landscape of rare disease treatment.
NASDAQ:RLYBLong
by DEXWireNews
JNJ has bottomed and can rise by +50%Johnson & Johnson gives a very clear idea of its trend on the 1M timeframe. The price may be under the 1D MA50 but has reached the bottom of the multi year Channel Up that started at the bottom of the 2008-2009 crisis. Being neutral on the 1M technical outlook (RSI = 45.714, MACD = -1.180, ADX = 20.525) has historically been one of the best buy opportunities, in fact the stock has grown by at least +53.04% three time during that time span. We shouldn't also ignore the fact that the 1M MA100 is still holding and has been doing so since June 2012. We are aiming long term for at least +53.04% again (TP = 220.00). ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##
NYSE:JNJLong
by InvestingScope
JOHNSON & JOHNSON More pain along the way. SELL.Johnson & Johnson (JNJ) got rejected on its 1D MA200 (orange trend-line) - 1D MA50 (blue trend-line) Resistance Zone. It has been practically trading sideways since the start of the year and based on the Sine Waves, that priced the new Top (Lower Highs trend-line) of the 2-year Channel Down pattern. The expected completion of a Bearish Cross this week on the 1W RSI, will confirm the Sell Signal, as all 3 previous Bearish Cross sequences were forme just after a Top. Though their declines ranged from -17.58% to -14.78%, we will use the October 10 2022 Low as an example and target the 0.9 Fibonacci retracement level at 147.00 as since the Bullish Leg was limited, we expect an equally less aggressive Bearish Leg towards the bottom of the Sine Waves. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:JNJShort
by TradingShot
Pharmaceutical Giants Stocks: Macro Fib SchematicsThe biggest pharma giants are easy to recognize. Johnson and Johnson, Pfizer, Moderna, Merck & Co, Danaher Corp, Thermo Fisher Scientific. All medications and pharmaceutical drugs come out of these drug corporations. Lab equipment, medical research, vaccines, and other life science developments come out of these conglomerate pharma giants. Support and Resistance is clear with these schematics. All clusters are laid over appropriately.
NASDAQ:MRNA
by MichaelBsul
JOHNSON & JOHNSON Double buy entry.JNJ touched Support (1) at 153.20, a level holding since June 1st. Along with Support (2) at 150.10 are the major buy levels for the long term. The medium term Resistance is the MA200 (1d). Trading Plan: 1. Buy on the current market price. 2. If Support (1) breaks, buy on Support (2). Targets: 1. 162.00 (expected contact point with the MA200 (1d)). 2. 161.00 (expected contact point with the MA200 (1d)). Tips: 1. The RSI (1d) shows that the stock price in the past 12 months bottoms a little after the RSI forms a Double Bottom. It makes a slightly lower low. Be on the look out for one. Please like, follow and comment!!
NYSE:JNJLong
by TradingBrokersView
KVUE Split-off: A Response to JNJ's Cancer-Related Products?It is plausible to consider that Johnson & Johnson's decision to spin off Kenvue might be linked to an effort to mitigate potential legal liabilities stemming from its talc-based products, which have been implicated in cases of cancer in the US and Canada. This strategic maneuver could potentially offer a layer of legal protection. Shareholders are expected to transition from holding Johnson & Johnson shares to Kenvue shares in the upcoming week. A similar approach was attempted by MMM, although it did not yield successful results, causing a downward trajectory in its stock performance over the past two years. From my perspective, the true rationale behind the division appears to be related to the numerous instances of individuals developing cancer due to Johnson & Johnson's talc-based products. A recent legal ruling mandated Johnson & Johnson to pay $18.8 million to a California resident who claimed to have contracted cancer from using its baby powder. This decision represents a setback for the company as it seeks resolution for thousands of comparable cases related to its talc-based products within a US bankruptcy court. Johnson & Johnson recently disclosed detailed information regarding the much-anticipated division of its consumer healthcare venture, Kenvue. This move involves a separation of at least 80.1% of Kenvue shares, facilitated through an exchange offer presented to investors. Within this arrangement, shareholders have the flexibility to trade all, a portion, or none of their Johnson & Johnson shares for Kenvue stock. The company is extending the choice to its investors, allowing them to opt for an exchange of shares for Kenvue stock. To incentivize this exchange, a 7% discount is being offered on the shares. However, there is an upper threshold of 8.0549 Kenvue shares for each Johnson & Johnson share. If this ceiling is not applicable, shareholders will receive approximately $107.53 worth of Kenvue shares for every $100 worth of Johnson & Johnson stock they intend to exchange. The execution of this exchange offer is anticipated to conclude by mid-August. Notably, this exchange program is voluntary and carries tax-free advantages. Kenvue has outlined plans to distribute a portion of its available funds to shareholders through dividend payments. The company has recently initiated a quarterly dividend of $0.20 per share (equivalent to $0.80 annually), with the first payout scheduled for early September. This dividend framework translates to a dividend yield of 3.3% based on the prevailing stock price of approximately $24 per share. This yield marginally exceeds Johnson & Johnson's existing dividend yield of 2.8%. It is likely that a significant portion of individuals holding Johnson & Johnson stock will opt to exchange their shares for Kenvue. Based on this assessment, I anticipate that Kenvue's stock could potentially reach $30 in the near future. Looking forward to read your opinion about it!
NYSE:KVUELong
by TopgOptions
JOHNSON & JOHNSON Buy opportunity.Johnson & Johnson is trading inside an Ascending Triangle pattern with the 1D technicals neutral (RSI = 49.652, MACD = -0.360, ADX = 36.021). The 1D MACD is close to making a Buy Cross so today's cross over the 1D MA50 is a first buy signal, that targets the 1D MA200 (TP = 165.00). If the price crosses over the R1 (167.25) we will buy again targeting the R2 (TP = 181.15), which is exactly on the 2.0 Fibonacci extension level. ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##
NYSE:JNJLong
by InvestingScope
1
Johnson & Johnson (JNJ) | Inside an Optimal Buying Zone!Hi, The market has made some pretty good moves up and the current slight correction is bringing prices back to technically good levels and Johnson & Johnson is one of them. Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer goods. Technically, it has been quite difficult to get it (when there has been such a clear and strong trend, you don't have to be smart to understand that the fundamentals are fine with JNJ), because there have not been such sharp reversals, from which to find a support level and etc, but as you can see from the picture, it has not been impossible. Namely, the price of JNJ has respected a trendline for almost 10 years. The trend line is drawn from the closing prices (you can do it easily on the line chart) to eliminate the noise and the wicks that the various waves of panic have brought. JNJ has always been bought up very quickly and the growth has been steady. Also, the price has respected the 50-month moving average (50EMA) almost flawlessly, and at the moment the trend line and the EMA50 form a single punch and are together in one price zone. Technical criteria for a significant level of support: 1. Trendline, clearly proven in the long term. 2. The Monthly EMA50 has held nicely. 3. The resistance level that worked for three years in 2017-2020, around $150, will start working as a support level. 4. Short-term channel projection 5. Short-term equal waves from the top: AB=CD The optimal entry point should stay between $147-$160. Good luck!
NYSE:JNJLong
by VaidoVeek
JOHNSON & JOHNSON Can reach $190 by FebruaryJohnson & Johnson (JNJ) has been trading within a long-term Bullish Megaphone pattern since the January 26 2021 High. The pattern has been having very structured Higher Highs and Higher Lows. At the moment the stock is on a bullish leg, after rebounding exactly on the 1D MA50 (blue trend-line) on November 11 and is also above the 1D MA200 (orange trend-line). The 1W MACD is on a Bullish Cross and the 1W RSI rebounded off a Lower Lows (Double) Bottom formation. The exact same sequence was last seem early this year on January. After one last pull-back, the stock then rallied to the top (Higher Highs trend-line) of the Bullish Megaphone. The Higher Highs seem to be following the 1.236 - 1.5 - 1.786 Fibonacci sequence and so do the Lows (0.236 - 0.5 - 0.786). The 1.786 Fib extension is a little over $190.00 and that is our current long target on JNJ. ------------------------------------------------------------------------------- ** Please LIKE 👍, SUBSCRIBE ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support me, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- You may also TELL ME 🙋‍♀️🙋‍♂️ in the comments section which symbol you want me to analyze next and on which time-frame. The one with the most posts will be published tomorrow! 👏🎁 ------------------------------------------------------------------------------- 👇 👇 👇 👇 👇 👇 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:JNJLong
by TradingShot
2
JNJ presenting a BUY LEVELNYSE:JNJ The Conservative Stop offers less exposition and a great Risk/Reward Ratio of 5 at the risk of being too tight .While the wide stop offers much more room for the trade at the expense of a lesser Risk/Reward Ratio around 3.5 . Whatever your style ,trading is a game of probabilities and the bulk of the profit if not all the significant profit is realised on a long serie of trades and not solely on a single trade . Results of any Individual trade shrink to insignificance when compared to the sum total of the long serie of trades . At the same time it is important to stick each time to your edge on the market in order to profit on the long term . Enthusiastically Brought to You by ManhattanStocks All Requests Suggestions and Remarks are Welcome
NYSE:JNJLong
by manhattanstocks
Johnson and Johnson at Key Resistance? Johnson and Johnson - Short Term - We look to Sell at 176.93 (stop at 178.95) Previous resistance located at 176.00. We look to sell rallies. This provides an excellent risk/reward opportunity to fade the current bullish move. Although the anticipated move lower is corrective, it does offer ample risk/reward today. Our profit targets will be 172.09 and 168.20 Resistance: 176.00 / 180.00 / 200.00 Support: 170.00 / 165.00 / 155.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading . The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NYSE:JNJShort
by Saxo
Johnson and Johnson loosing ground. JNJImmediate targets at 165, 156, 149. Invalidation at 194. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe
NYSE:JNJShort
by Rykin_Capital